MRI compatible cardiac pacemakers and implantable cardioverter defibrillators
Authors:
Michal Šnorek 1; Alan Bulava 1,2
Authors‘ workplace:
Kardiocentrum - kardiologické oddělení, Nemocnice České Budějovice, a. s., přednosta prim. MUDr. František Toušek, FESC
1; Zdravotně sociální fakulta Jihočeské univerzity v Českých Budějovicích, děkanka prof. PhDr. Valérie Tóthová, Ph. D.
2
Published in:
Vnitř Lék 2014; 60(2): 123-127
Category:
Review
Overview
Implanted cardiac pacemaker (PM) or implantable cardioverter defibrillator (ICD) has been so far considered a contra-indication to magnetic resonance imaging (MRI). In the last few years MRI conditional cardiac implantable electronic devices have been marketed enabling patients undergo MRI under specific conditions. We present current state of the art and provide overview of available MRI conditional devices. Magnetic resonance imaging in these patients should be performed only in cases where the requested information can not be obtained using alternative imaging technique.
Key words:
cardiac pacemaker – implantable cardioverter defibrillator – magnetic resonance imaging
Sources
1. Kalin R,Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. Pacing Clin Electrophysiol 2005; 28(4): 326–328.
2. Mechl M, Žižka J, Tintěra J et al. Kontraindikace a rizika vyšetření pomocí magnetické rezonance. Ces Radiol 2010; 64(1): 69–75.
3. Harden SP. MRI conditional pacemakers: the start of a new era. Br J Radiol 2011; 84(1005): 773–774.
4. Táborský M, Kautzner J, Křivan L et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 51(9): 602–614.
5. Vardas PE, Auricchio A, Blanc JJ et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007; 28(18): 2256–2295.
6. Dickstein K, Vardas PE, Auricchio A et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010; 31(21): 2677–2687.
7. Epstein AE, Dimarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117(21): e350-e408. Dostupné z DOI: < http://doi: 10.1161/CIRCUALTIONAHA.108.189742>.
8. Tracy CM, Epstein AE, Darbar D et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2012; 126(14): 1784–1800.
9. Hundley WG, Bluemke DA, Finn JP et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 121(22): 2462–2508.
10. Cronin EM, Mahon N, Wilkoff BL. MRI in patients with cardiac implantable electronic devices. Expert Rev Med Devices 2012; 9(2): 139–146.
11. Mitka M. First MR safe pacemaker receives conditional approval from FDA. JAMA 2011; 305(10): 985–986.
12. Shinbane JS, Colletti PM, Shellock FG. MR imaging in patients with pacemakers and other devices: engineering the future. JACC Cardiovasc Imaging 2012; 5(3): 332–333.
13. BIOTRONIK Introduces the World’s First and Only Implantable Defibrillators Eligible for Magnetic Resonance Imaging [online]. 2011.Dostupné z WWW:<http://www.biotronik.com>.
14. Nazarian S, Hansford R, Roguin A et al. A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. Ann Intern Med 2011; 155(7): 415–424.
15. Wilkoff BL, Bello D, Taborsky M et al. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. Heart Rhythm 2011; 8(1): 65–73.
16. Vymazal J, Táborský M, Žáček R. Vyšetření magnetickou rezonancí s implantovaným kardiostimulátorem EnRhythm MRI SureScan s MR kompatibilními elektrodami CapSureFix MRI – první zkušenosti. Ces Radiol 2009; 63(1): 9–12.
17. Naehle CP, Kreuz J, Strach K et al. Safety, feasibility, and diagnostic value of cardiac magnetic resonance imaging in patients with cardiac pacemakers and implantable cardioverters/defibrillators at 1.5 T. Am Heart J 2011; 161(6): 1096–1105.
18. Bhandiwad AR, Cummings KW, Crowley M et al. Cardiovascular magnetic resonance with an MR compatible pacemaker. J Cardiovasc Magn Reson 2013; 15: 18. Dostupné z DOI: <http://doi: 10.1186/1532–429X-15–18>.
19. Quarta G, Holdright DR, Plant GT et al. Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ. J Cardiovasc Magn Reson 2011; 13: 26. Dostupné z DOI: < http://doi: 10.1186/1532–429X-13–26>.
20. Raj V, O’Dwyer R, Pathmanathan R et al. MRI and cardiac pacing devices – beware the rules are changing. Br J Radiol 2011; 84(1005): 857–859.
21. Colletti PM, Shinbane JS, Shellock FG. “MR conditional” pacemakers: the radiologist’s role in multidisciplinary management. AJR Am J Roentgenol 2011; 197(3): W457-W459. Dostupné z DOI: <http://doi: 10.2214/AJR.11.7120>.
22. Reynolds MR, Zimetbaum P. Magnetic resonance imaging and cardiac devices: how safe is safe enough? Ann Intern Med 2011; 155(7): 470–472.
23. Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34(29): 2281–2329.
24. BIOTRONIK ProMRI product portfolio [online] 2013. Dostupné z WWW: <http://www.biotronik.com>.
25. REVEAL® DX 9528. Implantabilní srdeční monitor. Příručka pro lékaře [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
26. Reveal XT 9529. Implantabilní srdeční monitor. Příručka pro lékaře [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
27. Advisa DR MRI SureScan A3DR01. Informace o magnetické rezonanci [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
28. Advisa MRI SureScan Pacing System [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
29. EnRhythm MRI SureScan EMDR01. Informace o magnetické rezonanci (MRI).Technická příručka [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
30. Revo MRI SureScan Pacing System. MRI. Technical Manual. [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
31. Ensura DR MRI SureScan EN1DR01. Informace o magnetické rezonanci (MRI) [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
32. Medtronic SureScan: MRI and Pacemaker Trends [online]. Dostupné z WWW: <http://www.manuals.medtronic.com>.
33. Accent MRITM Pacemaker [online]. 2013 [cit. 2013–05–04]. Dostupné z WWW: <http://www.sjmprofessional.com>.
34. Boston Scientific – The ImageReadyTM MR Conditional pacing system [online]. Dostupné z WWW: <http://www.bostonscientific.com>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2014 Issue 2
Most read in this issue
- MRI compatible cardiac pacemakers and implantable cardioverter defibrillators
- Dynamics of interleukin 6 levels in the patients with cardiogenic and septic shock and in a control group of patients with uncomplicated AMI
- Catheter Related Septic Central Venous Thrombosis of the Superior Vena Cava and Right Atrium
- The place of JAK2 inhibitors in the treatment of myelofibrosis. An amendment to the recommendations for diagnosis and treatment of Ph negative myeloproliferations of the Czech group for Ph- myeloproliferative disorders (CZEMP)